Reem J Al Argan, Mona H Ismail, Dania M Alkhafaji, Raed M Alsulaiman, Fatimah E Ismaeel, Reem S AlSulaiman, Ali N Almajid, Lameyaa Alsheekh, Tariq S Alsaif, Alaa A Alzaki, Safi G Alqatari, Abrar J Alwaheed, Abir H Al Said, Marwan J Al Wazzeh, Abdulaziz A AlQurain
{"title":"Gastrointestinal manifestations of COVID-19 in a single center in the Eastern Province of Saudi Arabia.","authors":"Reem J Al Argan, Mona H Ismail, Dania M Alkhafaji, Raed M Alsulaiman, Fatimah E Ismaeel, Reem S AlSulaiman, Ali N Almajid, Lameyaa Alsheekh, Tariq S Alsaif, Alaa A Alzaki, Safi G Alqatari, Abrar J Alwaheed, Abir H Al Said, Marwan J Al Wazzeh, Abdulaziz A AlQurain","doi":"10.4103/sjg.sjg_547_21","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Several gastrointestinal (GI) symptoms have been associated with novel coronavirus disease-2019 (COVID-19). Their prevalence and relation to the severity and hospital outcome of COVID-19 have not been well reported in the Middle East and Saudi Arabia. We aimed to examine the GI manifestations of COVID-19 and their association with the severity and hospital outcome of COVID-19 infection.</p><p><strong>Methods: </strong>We conducted a retrospective observational study of hospitalized COVID-19 patients who had a positive SARS-COV2 PCR test and were admitted at a university hospital in Saudi Arabia, from March to September 2020. The primary objective of the study was to describe the GI manifestations of COVID-19. The secondary objective was to investigate the association of GI manifestations with severity and outcome of COVID-19 infection.</p><p><strong>Results: </strong>We included 390 patients, of which 111 (28.5%) presented with GI manifestations. The most common presentation was diarrhea followed by nausea, vomiting, and abdominal pain. Patients without GI manifestations had a higher risk of severe-critical COVID-19 infection evident by the development of lung infiltration in more than 50% of lung fields within 24-48 h, acute respiratory distress syndrome, altered mental status, multiorgan failure, and cytokine storm syndrome (P < 0.05). These patients had a higher mortality rate compared to patients with GI manifestations (P = 0.01). A lower odds of death was seen among patients with GI symptoms (AOR 0.36; 95% CI, 0.158-0.82; P = 0.01).</p><p><strong>Conclusion: </strong>COVID-19 infection presents commonly with GI manifestations. Patients with GI manifestations have less severe COVID-19 disease and lower mortality rates.</p>","PeriodicalId":520774,"journal":{"name":"Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association","volume":" ","pages":"218-224"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/93/01/SJG-28-218.PMC9212119.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/sjg.sjg_547_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Background: Several gastrointestinal (GI) symptoms have been associated with novel coronavirus disease-2019 (COVID-19). Their prevalence and relation to the severity and hospital outcome of COVID-19 have not been well reported in the Middle East and Saudi Arabia. We aimed to examine the GI manifestations of COVID-19 and their association with the severity and hospital outcome of COVID-19 infection.
Methods: We conducted a retrospective observational study of hospitalized COVID-19 patients who had a positive SARS-COV2 PCR test and were admitted at a university hospital in Saudi Arabia, from March to September 2020. The primary objective of the study was to describe the GI manifestations of COVID-19. The secondary objective was to investigate the association of GI manifestations with severity and outcome of COVID-19 infection.
Results: We included 390 patients, of which 111 (28.5%) presented with GI manifestations. The most common presentation was diarrhea followed by nausea, vomiting, and abdominal pain. Patients without GI manifestations had a higher risk of severe-critical COVID-19 infection evident by the development of lung infiltration in more than 50% of lung fields within 24-48 h, acute respiratory distress syndrome, altered mental status, multiorgan failure, and cytokine storm syndrome (P < 0.05). These patients had a higher mortality rate compared to patients with GI manifestations (P = 0.01). A lower odds of death was seen among patients with GI symptoms (AOR 0.36; 95% CI, 0.158-0.82; P = 0.01).
Conclusion: COVID-19 infection presents commonly with GI manifestations. Patients with GI manifestations have less severe COVID-19 disease and lower mortality rates.